The Executive Director, Health Economics & Outcomes Research (HEOR) will provide strategic leadership for the development and execution of health economics, outcomes research, real-world evidence, patient-reported outcomes and evidence synthesis strategies across Travere Therapeutics' nephrology portfolio, including FILSPARI (sparsentan), civorebrutinib, and future pipeline assets. The Executive Director will partner closely with Medical Affairs, Clinical Development, Market Access, Commercial, Regulatory Affairs, Biostatistics, and other cross-functional partners to identify evidence needs and ensure generation of high-quality data that supports scientific exchange, patient access, clinical development, and future value demonstration.